Navigation Links
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Date:1/9/2008

ve a number of known and unknown risks and uncertainties that could cause Pharmion's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include, but are not limited to, the potential failure of MGCD0103, to demonstrate safety and efficacy in clinical and non-clinical testing; the ability to complete regulatory submissions and gain regulatory approvals in a timely manner; the ability to initiate and complete trials at the referenced times; the impact of competition from other products under development by Pharmion's competitors; the uncertainty of the regulatory environment and changes in the health policies of various countries; acceptance and demand for new pharmaceutical products and new therapies; uncertainties regarding market acceptance of products newly launched, currently being sold or in development; failure of third-party manufacturers to produce the product volumes required on a timely basis and fluctuations in currency exchange rates. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
5. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)...   Zacks Equity Research highlights Epizyme (Nasdaq: EPZM ... Panera (Nasdaq: PNRA - Free Report ) as the Bear ... Amicus Therapeutics (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: ... - Free Report ). Here is a synopsis of ... : The biotech bull market is far from ...
(Date:8/22/2014)... Aug. 22, 2014  Mark Riccio, director of ... facility, is using the online crowd-funding platform Kickstarter ... imaging to researchers and would-be superheros everywhere: "for ... would YOU do if you had Superman,s X-ray ... and explorers everywhere, from elementary through high school ...
(Date:8/22/2014)... , Aug. 22, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... that William E. Saxelby , its President and ... and Chief Executive Officer and as a member of ... 2014.  He will be replaced on an interim basis ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2Landauer, Inc. Announces Executive Management Change 2
... BEIJING, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... "Company"), an emerging leader in the development, assembly, marketing ... in China, today announced that it will hold a ... quarter and nine months ended September 30, 2010. The ...
... KNDL ), a leading, global full-service clinical research ... Lazard Capital Markets 7th Annual Healthcare Conference on Nov. 16, ... City. Kendle,s formal presentation will be given at ... President and Chief Operating Officer and Keith Cheesman, Senior Vice ...
Cached Medicine Technology:Dehaier Medical Announces Conference Call to Discuss Third Quarter 2010 Financial Results 2Kendle to Present at Lazard Capital Markets 7th Annual Healthcare Conference 2
(Date:8/22/2014)... 2014 Eagerly embracing intended parents around ... and now offers the top male infertility programs — ... The fertility network of IVFinMexico.com continues to ... reproductive care, female and male infertility, advanced research and ... standards so eminently set by company CEO and Founder ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- An intensive effort ... to an animal shelter in Florida and euthanized, a new ... enough cats to slow their intake into animal control," Dr. ... of Florida College of Veterinary Medicine, said in a university ... there wasn,t making a big impact," she explained, "so we ...
(Date:8/22/2014)... August 22, 2014 A national leader in ... new offices with room to grow. , Headquarters for the ... a 60,000-square-foot office building at 8516 N.W. Expressway in Oklahoma ... one of the Oklahoma’s best places to work by OKCBiz ... company has hired 120 in the past two years, and ...
(Date:8/22/2014)... 2014 Home Care Assistance of ... for seniors, is proud to announce the next installment ... webinar will feature Dr. Suzanne Steinbaum, attending cardiologist and ... in New York City, National Spokesperson for the American ... will cover the issues surrounding women and heart disease, ...
(Date:8/22/2014)... -- Inner city children have a higher-than-normal risk of developing ... inner city children in four U.S. cities -- Baltimore, Boston, ... 5 and found that at least 10 percent of them ... only the three most common types of food allergies were ... youngsters with food allergies may be even higher, the researchers ...
Breaking Medicine News(10 mins):Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 2Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 4Health News:Neutering Project Curbed Feral Cat Population 2Health News:Fast-growing 180 Medical Moves Into New 60,000-square-foot Office in Oklahoma City 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Food Allergies More Common Among Inner City Kids, Study Finds 2
... common blood thinners also are taken , , FRIDAY, March 13 ... appears to be safe and tolerable in preventing blood ... at the Duke Clinical Research Institute. , The trial included ... undergo either percutaneous coronary intervention (PCI) -- a procedure to ...
... Cherubs(R) Spokeskid in the ,Be the Next Sweet Sensation, ... about NatureSweet(R) Cherubs(R) bite-sized tomatoes as the sweetest snacking ... for kids entitled "Be the Next Sweet Sensation". The ... program including online, retail, print, PR and radio support. ...
... a continued effort to provide perioperative solutions that ... and safer care, Surgical Information Systems (SIS) now ... Solution to Pyxis Supply Technologies; a division of ... of economic uncertainty, it is now more important ...
... Unnecessarily Every Year From Preventable Medical Errors , ... ... National Patient Safety Awareness Week , Quantros , a ... industry, has produced an educational video that exposes the staggering numbers ...
... Refugee Health and Human Rights (BCRHHR) at Boston ... number of Tibetan refugee monks who fled violent ... from symptoms of traumatic stress, interfering with their ... traditional healers as having srog-rLung, a life-wind imbalance. ...
... The National Association of Boards of Pharmacy(R) (NABP(R)) is ... Award of Excellence in the first round of the ... competition sponsored by the American Society of Association Executives ... based in Mount Prospect, IL, received the award for ...
Cached Medicine News:Health News:Investigational Drug May Help Avert Blood Clots 2Health News:NatureSweet(R) Celebrates Snacking With an Online Natural Talent Show 2Health News:SIS Offers Increased Financial and Operational Efficiencies with Pyxis Supply Technologies 2Health News:Quantros Produces Video Detailing Enormous Problem of Preventable Medical Errors Plaguing The U.S. Healthcare System 2Health News:Quantros Produces Video Detailing Enormous Problem of Preventable Medical Errors Plaguing The U.S. Healthcare System 3Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 2Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 3Health News:NABP Wins ASAE's 2009 Associations Advance America Award of Excellence 2Health News:NABP Wins ASAE's 2009 Associations Advance America Award of Excellence 3
The DFS MiniFixator is a lightweight, external device for the treatment of small bone fractures and osteotomies....
The Elbow Fixator has ontrolled movement about the axis of rotation of the elbow joint. It is minimally invasive and rapidly applied....
... tradition of the original Hoffmann® Fixator, ... surgeon with advanced technology and ease ... snap fit mechanism allows the easy ... or pins providing versatile intraoperative frame ...
... safe and effective nonionic contrast medium well ... Worldwide, more than 250 million doses ... for a wide variety of radiological procedures, ... wide range of iodine concentrations and packaging ...
Medicine Products: